prostate cancer

prostate cancer
Field	Oncology, Urology

prostate cancer. It is a form of cancer that develops in the prostate, a gland in the male reproductive system. Most prostate cancers are slow-growing, but some types can be aggressive and spread quickly. The disease is a major focus of research in fields like oncology and urology.

Signs and symptoms

Early stages often present no symptoms. As the disease progresses, symptoms may include difficulty urinating, blood in the urine or semen, and pain in the pelvis, back, or hips. These symptoms can be similar to those of benign prostatic hyperplasia. Erectile dysfunction may also occur. If the cancer metastasizes to bones, it can cause significant bone pain, often in the spine, femur, pelvis, ribs, or skull. Metastasis to the lymph nodes can cause swelling in the legs or discomfort.

Risk factors

The strongest known risk factor is advancing age, with most cases diagnosed in men over 65. Family history and genetics play a significant role; mutations in genes like BRCA1 and BRCA2 increase risk. Race and ethnicity are factors, with higher incidence and mortality rates observed among African American men compared to Caucasian or Asian American men. Other potential factors include a diet high in red meat or dairy products and certain chemical exposures. Some studies suggest a link with prostatitis or sexually transmitted infections, though evidence is not conclusive.

Diagnosis

Diagnosis typically begins after an abnormal digital rectal exam or an elevated prostate-specific antigen blood test. The definitive diagnosis is made by a pathologist following a prostate biopsy, often guided by transrectal ultrasonography. Gleason grading of the biopsy tissue is critical for determining aggressiveness. Advanced imaging techniques like multiparametric magnetic resonance imaging are increasingly used to guide biopsies and assess the disease. Other tests may include a bone scan or CT scan to check for spread to bones or lymph nodes.

Screening

Screening is controversial and involves the prostate-specific antigen blood test and the digital rectal exam. Major health organizations like the United States Preventive Services Task Force, the American Cancer Society, and the American Urological Association have differing guidelines on routine screening, emphasizing shared decision-making due to risks of overdiagnosis. Screening is generally recommended for men between 55 and 69 years old. The European Association of Urology also provides guidance, and research into improved biomarkers is ongoing at institutions like the National Cancer Institute.

Treatment

Treatment depends on the cancer's stage and grade, and the patient's age and health. Options for localized disease include active surveillance, radical prostatectomy (surgery), and radiation therapy (including external beam radiation therapy and brachytherapy). Advanced or metastatic disease is often treated with androgen deprivation therapy, which may involve drugs like leuprolide or surgical removal of the testicles (orchiectomy). Newer treatments include chemotherapy (e.g., docetaxel), immunotherapy (e.g., sipuleucel-T), and targeted therapies like PARP inhibitors for those with specific genetic mutations. Institutions like the Mayo Clinic and Memorial Sloan Kettering Cancer Center are leaders in treatment research.

Prognosis

Prognosis is generally excellent when detected early, with a high five-year survival rate for localized disease. The Gleason score and TNM staging system are key prognostic indicators. Survival rates drop significantly if the cancer spreads to distant organs like bones. Treatments such as androgen deprivation therapy can control advanced disease for years, though many cancers eventually become castration-resistant prostate cancer. Ongoing clinical trials at centers like the Dana-Farber Cancer Institute and the MD Anderson Cancer Center continue to seek improved outcomes. The Prostate Cancer Foundation funds extensive research into better prognostic tools and therapies.

Category:Urology Category:Oncology